Contact usContact us

The Company

Domain Therapeutics, a French and Canadian privately-held biopharmaceutical company, is using transmembrane and G Protein-Coupled Receptor (GPCR) targeting for the discovery and development of innovative therapeutics for the treatment of Central Nervous System (CNS) diseases and cancer.

Using its commercially proven candidate discovery engine (Takeda, Merck Serono and ONO Pharmaceutical), Domain has created a pipeline of high-value projects and partnerships. Validating this approach, two projects discovered by Domain Therapeutics technologies are planned to enter clinical Phase I in early and late 2016.

Domain Therapeutics applies a multi-string corporate strategy to grow its business through:

  • validation of its technologies through collaborative partnerships with Pharma/Biotechs,
  • generation of an internal pipeline of 1st in class drug candidates for high unmet needs in CNS and oncology,
  • valuation of its preclinical assets through spin-out vehicles, financed by leading investment funds or supported by development-only companies.

Domain Therapeutics
Last News

August 23, 2017

Domain Therapeutics will attend the 9th International Meeting on Metabotropic Glutamate Receptors, October 1st -6th in Taormina, Sicily, and co-present with Prexton Therapeutics a poster about the discovery, characterization and anti-parkinsonian effect of a novel mGluR4 PAM chemical series that led to Foliglurax, the first mGluR4 PAM compound in clinical trial

9th International meeting on metabotropic glutamate receptors, learn more...


May 10, 2017

New dedicated bioSensAll™ website launched 

Learn more...


APRIL 25, 2017

Pfizer Inc. and Domain Therapeutics enter into a collaboration agreement on bioSensAll™ 

MARCH 15, 2017

PeptiMimesis receives second tranche of seed funding to further advance its transmembrane peptide pipeline

Learn more...